Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diomed v. Total Vein Solutions

This article was originally published in The Gray Sheet

Executive Summary

Patent suit is filed over varicose vein endovascular laser treatment, Diomed says April 5. Separate actions are pending against AngioDynamics and Vascular Solutions (1"The Gray Sheet" Dec. 22, 2003, p. 6)...

You may also be interested in...



AngioDynamics Foresees New Laser Sales Opportunities With Sotradecol Drug

AngioDynamics expects to expand into hitherto untargeted markets with the help of its newly licensed Sotradecol drug for the treatment of small, uncomplicated varicose veins

Litigation In Brief

Medinol v. Boston Scientific: Injunction against sales of Boston Scientific Express stents and 30% royalty payments to Medinol on Taxus drug-eluting stents applies only to The Netherlands, Hague district court rules. Court finds device infringes one Dutch counterpart of four European patents asserted by Medinol. Boston Scientific, which will appeal the decision, notes that "neither the injunction nor potential damages will be material," because total 2003 sales of the devices in The Netherlands will be only about $10.6 mil. Meanwhile, Medinol's request for cross-border relief in 16 European countries is denied. The ruling follows a June 24 Dusseldorf, Germany district court finding that Boston Scientific infringed Medinol patents in that country (1"The Gray Sheet" June 30, 2003, p. 22). Related New York federal court litigation between the firms is ongoing (2"The Gray Sheet" Dec. 8, 2003, p. 23)...

At Muted J.P. Morgan, Focus Is Execution, But US Pricing Is Persistent Overhang

Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.

UsernamePublicRestriction

Register

MT020043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel